E01V0003 Human Nicotinamide phosphoribosyltransferase/ Visfatin ELISA kit
The Human Nicotinamide phosphoribosyltransferase/ Visfatin ELISA kit can be used to identify samples from the human species. Nicotinamide phosphoribosyltransferase/ Visfatin can also be called NAmPRTase/NAMPT/VF, Nampt, NAmPRTase, PBEF, PBEF1, Pre-B-Cell Colony Enhancing Factor, Nicotinamide Phosphoribosyltransferase.
Product Information | |
Cat. No. | E01V0003 |
Product Name | Human Nicotinamide phosphoribosyltransferase/ Visfatin ELISA kit |
Species | Human |
Product Size | 48 Tests / 96 Tests |
Concentration | 50-1000 ng/ml |
Sensitivity | 1.0 ng/ml |
Principal | Competitive ELISA |
Sample Volume | 100 ul |
Sample Type | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate |
Assay Time | 90 minutes |
Platform | Microplate Reader |
Conjugate | HRP |
Detection Method | Colorimetric |
Storage | 2-8°C |
Kit Components | ||
MATERIALS | SPECIFICATION | QUANTITY |
MICROTITER PLATE | 96 wells | stripwell |
ENZYME CONJUGATE | 6.0 mL | 1 vial |
STANDARD A (0.5mL) | 0 ng/mL | 1 vial |
STANDARD B (0.5mL) | 50 ng/mL | 1 vial |
STANDARD C (0.5mL) | 100 ng/mL | 1 vial |
STANDARD D (0.5mL) | 250 ng/mL | 1 vial |
STANDARD E (0.5mL) | 500 ng/mL | 1 vial |
STANDARD F (0.5mL) | 1000 ng/mL | 1 vial |
SUBSTRATE A | 6 mL | 1 vial |
SUBSTRATE B | 6 mL | 1 vial |
STOP SOLUTION | 6 mL | 1 vial |
WASH SOLUTION (100 x) | 10 mL | 1 vial |
BALANCE SOLUTION | 3 mL | 1 vial |
Principle of the Assay |
NAmPRTase/NAMPT/VF ELISA kit uses an anti-NAmPRTase/NAMPT/VF antibody and an NAmPRTase/NAMPT/VF-HRP conjugate in a competitive enzyme immunoassay method. NAmPRTase/NAMPT/VF-HRP conjugate is incubated with the assay sample and buffer in a pre-coated plate for one hour. The wells are decanted and washed five times when the incubation period is over. The HRP enzyme substrate is then incubated in the wells. The result of the enzyme-substrate reaction is a complex that is blue in hue. The process is finally stopped by adding a stop solution, causing the solution to turn yellow. In a microplate reader, the color intensity is measured spectrophotometrically at 450 nm. Due to competition for the anti-NAmPRTase/NAMPT/VF antibody binding site between NAmPRTase/NAMPT/VF from samples and NAmPRTase/NAMPT/VF-HRP conjugate, the intensity of the color is inversely proportional to the concentration of NAmPRTase/NAMPT/VF. Since the number of sites is limited, as more sites are occupied by NAmPRTase/NAMPT/VF from the sample, fewer sites are left to bind NAmPRTase/NAMPT/VF-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The NAmPRTase/NAMPT/VF concentration in each sample is interpolated from this standard curve. |
Coefficient of Variance | Intra Variation% ＜10% | |
Inter Variation% ＜12% | ||
Recovery | 95-102% | |
Linearity | Diluent Ratio | Range % |
1:2 | 93-105 | |
1:4 | 88-106 | |
1:8 | 86-108 | |
Specificity/Cross-reactivity | No significant cross-reactivity or interference between NAmPRTase/NAMPT/VF and analogues was observed. | |
E01V0003 has been referenced in the below publications：
High-density lipoprotein inhibits ox-LDL-induced adipokine secretion by upregulating SR-BI expression and suppressing ER Stress pathway.
Small for gestational age infants plasma visfatin levels and its clinical significance.
Study on the Change of Early Serum and Intestinal Immune Factors in the Small Intestine of Kazak Sheep.
The expression of visfatin and PPARγ in gestational diabetes and normal pregnants.
The clinical study of metabolic disorders and the correlation with Adipocytokines in PCOS women.
Related Bluegene Biotech Products
